Novartis (NVS)

Executive Summary

Novartis is a Swiss multinational pharmaceutical giant with a market cap of approximately $290B, spanning six advanced technology platforms including antibodies, biologics, RNA & gene therapy, and cell therapy. The company reaches nearly 300 million patients globally across 118 countries and has a robust portfolio of 59 commercial products. In 2025, Novartis delivered strong operational performance driven by key growth drivers such as Entresto, Cosentyx, and Kisqali, while advancing its pipeline in cardiovascular, immunology, and oncology. The company is well-positioned to capitalize on upcoming catalysts, including pivotal data readouts and regulatory decisions for high-potential assets. With a strategy focused on innovative medicines and disciplined capital allocation, Novartis remains a top-tier investment in the pharmaceutical sector.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on iptacopan for IgA nephropathy75% success
• Q4 2026Phase 3 topline data for remibrutinib in chronic spontaneous urticaria70% success
• H2 2026Phase 3 results for pelacarsen in cardiovascular disease65% success